Form 8-K - Current report:
SEC Accession No. 0001367644-25-000114
Filing Date
2025-05-06
Accepted
2025-05-06 16:19:14
Documents
14
Period of Report
2025-04-30
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ebs-20250430.htm   iXBRL 8-K 42582
  Complete submission text file 0001367644-25-000114.txt   198970

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ebs-20250430.xsd EX-101.SCH 2059
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ebs-20250430_def.xml EX-101.DEF 15289
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ebs-20250430_lab.xml EX-101.LAB 26957
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ebs-20250430_pre.xml EX-101.PRE 15991
16 EXTRACTED XBRL INSTANCE DOCUMENT ebs-20250430_htm.xml XML 2722
Mailing Address 300 PROFESSIONAL DR GAITHERSBURG MD 20879
Business Address 300 PROFESSIONAL DR GAITHERSBURG MD 20879 240-631-3200
Emergent BioSolutions Inc. (Filer) CIK: 0001367644 (see all company filings)

EIN.: 141902018 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33137 | Film No.: 25917545
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)